Pharming Group (NASDAQ:PHAR - Get Free Report)'s share price gapped down prior to trading on Thursday . The stock had previously closed at $12.16, but opened at $11.84. Pharming Group shares last traded at $11.66, with a volume of 1,916 shares trading hands.
Analysts Set New Price Targets
PHAR has been the subject of a number of recent research reports. HC Wainwright reissued a "buy" rating and set a $37.00 price objective on shares of Pharming Group in a report on Thursday, March 20th. Oppenheimer boosted their price objective on Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a report on Friday, March 14th.
Check Out Our Latest Research Report on PHAR
Pharming Group Price Performance
The business has a 50 day moving average price of $9.19 and a two-hundred day moving average price of $8.99. The stock has a market cap of $813.24 million, a PE ratio of -45.85 and a beta of 0.02. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.03. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The firm had revenue of $79.09 million for the quarter, compared to analysts' expectations of $67.74 million. Research analysts expect that Pharming Group will post -0.2 earnings per share for the current fiscal year.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
